Dr Reddys Laboratories
BSE 500124 · ISIN INE089A01031
32 stories, newest first.
- Dr Reddy's files audio and video recordings of October 23, 2026 earnings call on Q2/H1 FY27 results
- Auditor's limited review reports with UDIN on Q2 and H1 results
- Board approves appointment of Akhil Ravi as Head API and Services and Senior Management Personnel
- Board meeting outcome: Q2 and H1 FY27 unaudited results approved; Akhil Ravi named Head API and Services
- Q2 FY27 presentation: revenue ₹ 8,671 Cr, EBITDA ₹ 1,783 Cr at 20.6% margin, PAT ₹ 925 Cr
- Consolidated results for the quarter ended 30.09.2026
- Dr. Reddy's expected to report a weak year-on-year Q2 with revenue and profit declines, though sequential improvement anticipated
- Dr. Reddy's expected to report a revenue decline of around 4 percent this quarter, led by weakness in its US business
- Ajit Mishra recommended long positions in Dr. Reddy's on technical strength
- Dr. Reddy's receives DCGI approval for Zytorvi (toripalimab) in advanced esophageal squamous cell carcinoma in India
- Analyst expects Dr. Reddy's Semaglutide manufacturing issue to be resolved by Q3, enabling resumption of supplies to Canada, with a biosimilar approval decision for Avastin expected in December
- USFDA completes Pre-Approval Inspection at FTO-9 Visakhapatnam; Form 483 with three observations issued
- Jai Thacker recommended a buy call on Dr Reddy's Laboratories within the pharma pack
- USFDA completes Pre-Approval Inspection at FTO-11 plant; Form 483 with two observations issued
- Q2FY27 results on October 23rd, 2026; earnings call same day at 19:30 PM IST / 10:00 AM ET
- US IRS levies $32,350.20 penalty on step-down subsidiary over tax payment misclassification
- Citi upgraded Dr. Reddy's Laboratories to buy from sell, raising target price to Rs 1450
- Dr Reddy's was among the top Nifty gainers after a double upgrade from Citi
- Dr Reddy was among the top gainers on the Nifty after a double upgrade from Citi
- Analyst recommended buying Dr. Reddy's as stock tests its 200-day moving average with strong volumes
- Citi upgraded Dr Reddy's to buy, raising target price to around Rs 1450, citing biosimilar and margin outlook
- Citi double-upgrades Dr. Reddy's from sell to buy, stock outperforms in the pharma pack
- Citi double-upgraded Dr Reddy's from a sell to a buy, helping the stock outperform in the pharma pack
- Citi upgraded Dr Reddy's Labs with a raised target price, citing a 90-day positive catalyst call
- Citi upgraded Dr Reddy's Laboratories, raising target price on positive catalyst call citing semaglutide resumption
- Analyst Ajit Mishra recommended accumulating Dr. Reddy's as pharma sector trades at record highs
- DRL saw fresh long addition and was double-upgraded from sell to buy by Citi
- Citi upgraded Dr Reddy's Laboratories from sell to buy
- Dr. Reddy's shares surged 1.7% on Nomura's bullish call and updates on its semaglutide and abbitacept drug pipeline
- Dr Reddy's surged in trade after Nomura upgraded the stock by 2.5%, citing biosimilar milestones
- Dr Reddy's shares surged after Nomura maintained bullish call with a 2.5% target upgrade, citing biosimilar pipeline catalysts
- Dr. Reddy's stock up about 1.5%, top Nifty gainer amid weak market, following a bullish Nomura note
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.